These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12057121)

  • 1. Hairy cell leukemia.
    Savoie L; Johnston JB
    Curr Treat Options Oncol; 2001 Jun; 2(3):217-24. PubMed ID: 12057121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hairy-cell leukemia: current views.
    Tallman MS; Peterson LC; Hakimian D; Gillis S; Polliack A
    Semin Hematol; 1999 Apr; 36(2):155-63. PubMed ID: 10319384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hairy cell leukemia 1992.
    Spielberger RT; Golomb HM
    Leukemia; 1992 Nov; 6 Suppl 4():142-6. PubMed ID: 1279327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
    Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Rucińska M; Machaczka M; Załuska A; Skotnicki AB
    Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
    Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in therapy for hairy cell leukemia. A review.
    Jaiyesimi IA; Kantarjian HM; Estey EH
    Cancer; 1993 Jul; 72(1):5-16. PubMed ID: 7685243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
    Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
    Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
    Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
    Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
    Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
    Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatment options in hairy cell leukemia and hairy cell leukemia variant.
    Robak T
    Cancer Treat Rev; 2006 Aug; 32(5):365-76. PubMed ID: 16781083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
    Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
    Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
    Goodman GR; Burian C; Koziol JA; Saven A
    J Clin Oncol; 2003 Mar; 21(5):891-6. PubMed ID: 12610190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin.
    Saven A; Piro LD
    Ann Intern Med; 1993 Aug; 119(4):278-83. PubMed ID: 8101069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
    Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.
    Dearden CE; Matutes E; Hilditch BL; Swansbury GJ; Catovsky D
    Br J Haematol; 1999 Aug; 106(2):515-9. PubMed ID: 10460614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up.
    Seymour JF; Talpaz M; Kurzrock R
    Leukemia; 1997 Jan; 11(1):42-7. PubMed ID: 9001417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
    Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D
    Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recurrent somatic mutation in hairy cell leukemia].
    Sári E; Nagy Z; Demeter J
    Orv Hetil; 2013 Jan; 154(4):123-7. PubMed ID: 23335721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.